Medison Pharma announces multi-regional agreement with argenx to commercialize Efgartigimod
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Subscribe To Our Newsletter & Stay Updated